RGLS Showing Interesting LevelsRGLS continues pivoting around that 618 Fib line. Overall, it has held a clear uptrend despite the pullback. Trend line lines up almost perfectly with the latest higher lows put in. RNA companies remain a focus. In this case, it's not covid but kidney diseases.
"In mid-May, Regulus Therapeutics a
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.88 USD
−46.36 M USD
0.00 USD
53.18 M
About Regulus Therapeutics Inc.
Sector
Industry
CEO
Joseph P. Hagan
Website
Headquarters
San Diego
Founded
2007
FIGI
BBG000R33DR2
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
RGLS: Bullish Flag (47%)Bullish Flag (47%)
Pros:
Volume during post formation
Descending volume during Flag formation
Golden cross in blue
PPS above 50MA and 200MA
RS above 0
R/R ratio above 3
200MA ascending
Cons:
RS flat
ATR flat
250RSI below 50 and flat
Target:
PT = 2.73$
Help how ever you can to keep this alive.
Tha
RGLS RGLS .. We are in full phase two COVID-19. There are many aspects and many pharmaceutical companies that are trying to shine, especially in the research and experimentation of drugs of all kinds ... Let's add that a Master of Biotech finance like Steven Cohen buys 8.5% of shares (5.6 million shares
$RGLS is gonna fall todayPupm&Dump trading strategy idea.
$RGLS is rising without clear preconditions today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $0,95;
stop-loss — $1,08;
take-profit — $0,
$RGLS 40% upside potential Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatme
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of RGLS is 2.76 USD — it has increased by 9.80% in the past 24 hours. Watch Regulus Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Regulus Therapeutics Inc. stocks are traded under the ticker RGLS.
RGLS stock has risen by 45.83% compared to the previous week, the month change is a 113.74% rise, over the last year Regulus Therapeutics Inc. has showed a 21.59% increase.
We've gathered analysts' opinions on Regulus Therapeutics Inc. future price: according to them, RGLS price has a max estimate of 28.00 USD and a min estimate of 6.00 USD. Watch RGLS chart and read a more detailed Regulus Therapeutics Inc. stock forecast: see what analysts think of Regulus Therapeutics Inc. and suggest that you do with its stocks.
RGLS reached its all-time high on Nov 10, 2014 with the price of 3,072.00 USD, and its all-time low was 0.76 USD and was reached on Mar 20, 2023. View more price dynamics on RGLS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RGLS stock is 7.13% volatile and has beta coefficient of 0.49. Track Regulus Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Regulus Therapeutics Inc. there?
Today Regulus Therapeutics Inc. has the market capitalization of 185.48 M, it has increased by 15.73% over the last week.
Yes, you can track Regulus Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Regulus Therapeutics Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
RGLS earnings for the last quarter are −0.20 USD per share, whereas the estimation was −0.21 USD resulting in a 4.76% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Regulus Therapeutics Inc. earnings.
Regulus Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
RGLS net income for the last quarter is −12.79 M USD, while the quarter before that showed −14.06 M USD of net income which accounts for 9.04% change. Track more Regulus Therapeutics Inc. financial stats to get the full picture.
No, RGLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 26, 2025, the company has 34 employees. See our rating of the largest employees — is Regulus Therapeutics Inc. on this list?
Like other stocks, RGLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regulus Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Regulus Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Regulus Therapeutics Inc. stock shows the buy signal. See more of Regulus Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.